Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Total Debt
Short-term and long-term borrowings combined.
Alumis Inc. Common StockNASDAQ: ALMS
Total Debt · Q2 FY2026 · quarter ended Jun 2026
Total debt falls 6.1% from a year ago
Total debt stood at $36.43M at the end of Q2 FY2026, down 6.1% from a year earlier and up 2.1% from the prior quarter. Over 3 fiscal years it compounded at +174.8% a year.
Context
- Total debt amounted to 6.5% of total assets at the end of Q2 FY2026, up 0.2 pp from a year earlier.
- Total debt increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -6.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 36.91M USD
- Year-over-year change
- +20.2%
- 3-year CAGR
- +174.8%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 36.91M | +20.2% |
| FY2024 | 2024-12-31 | 30.72M | -5.7% |
| FY2023 | 2023-12-31 | 32.58M | +1731.4% |
| FY2022 | 2022-12-31 | 1.78M | — |
Total Debt vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so total debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -6.1% is the 6th highest of 9, against a peer median of +8.5%.
- Total debt amounts to 6.5% of total assets for ALMS, versus a peer median of 4.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $277.36M USD | +1680.8% | -10.1% | 84.1% | |
| Mar 2026 | $45.72M USD | -25.1% | +8.7% | 9.1% | |
ALMSAlumis Inc. Common Stock | Jun 2026 | $36.43M USD | -6.1% | +174.8% | 6.5% |
| Mar 2026 | $15.51M USD | -0.3% | -1.2% | 23.3% | |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $10.26M USD | -26.7% | -17.4% | 9.7% |
| Mar 2026 | $2.33M USD | +190.6% | -50.4% | 2.3% | |
| Mar 2026 | $1.99M USD | -20.1% | +45.7% | 1.0% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €1.33M EUR | — | — | 0.8% |
| Mar 2026 | €823.89K EUR | +17.3% | -12.9% | 1.7% | |
| Dec 2025 | $456K USD | +330.2% | +7.7% | 4.0% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ALMS) | — | +8.5% | -5.7% | 4.0% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.